Loading...
Loading...
PNT| Name | Value |
|---|---|
| Revenues | 4.9M |
| Cost of Revenue | 0.0M |
| Gross Profit | 4.9M |
| Operating Expense | 36.4M |
| Operating I/L | -31.5M |
| Other Income/Expense | 5.2M |
| Interest Income | 0.0M |
| Pretax | -26.3M |
| Income Tax Expense | -0.9M |
| Net Income/Loss | -25.4M |
POINT Biopharma Global Inc. is a radiopharmaceutical company specializing in the development and commercialization of radioligands for cancer treatment. Its lead product candidates, including PSMA-targeted radioligands for prostate cancer and somatostatin-targeted radioligands for neuroendocrine tumors, are in advanced clinical trials. The company also has next-generation product candidates for prostate cancer and a fibroblast activation protein-a targeting program for multiple tumor types in preclinical studies. Additionally, it is leveraging CanSEEK technology sub-licensed from Bach Biosciences LLC and Avacta Life Sciences Limited to develop innovative product candidates. POINT Biopharma generates revenue through the development and potential commercialization of its radioligand therapies.
